Telavancin Observational Use Registry (TOUR)

Trial Profile

Telavancin Observational Use Registry (TOUR)

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 08 Nov 2017

At a glance

  • Drugs Telavancin (Primary)
  • Indications Bacteraemia; Bone and joint infections; Endocarditis; Gram-positive infections; Nosocomial pneumonia; Skin and soft tissue infections
  • Focus Therapeutic Use
  • Acronyms TOUR
  • Sponsors Theravance Biopharma
  • Most Recent Events

    • 08 Nov 2017 Data from this registry are expected to be published in 2018, according to a Theravance Biopharma, Inc. media release.
    • 31 Oct 2017 According to a Theravance Biopharma media release, preliminary new data (n = 90) from this trial were presented at the 2017 CHEST annual meeting.
    • 31 Oct 2017 Preliminary new data (n = 90) presented in a Theravance BioPharma media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top